Noted This Week

Novartis announced that the FDA approved dabrafenib (Tafinlar) with trametinib (Mekinist) for children age 1 and older with low-grade glioma with a BRAF^V600E mutation. The agency also OK’d new oral formulations of both drugs for patients who cannot swallow pills. This is the first approval of a systemic therapy as an initial treatment for children with this condition.

More Noted This Week, March 10–16   »